Structure Therapeutics Inc. (GPCR)
NASDAQ: GPCR · Real-Time Price · USD
24.62
-0.95 (-3.72%)
At close: May 12, 2025, 4:00 PM
25.29
+0.67 (2.72%)
After-hours: May 12, 2025, 6:09 PM EDT
Structure Therapeutics Employees
Structure Therapeutics had 163 employees as of December 31, 2024. The number of employees increased by 70 or 75.27% compared to the previous year.
Employees
163
Change (1Y)
70
Growth (1Y)
75.27%
Revenue / Employee
n/a
Profits / Employee
-$879,282
Market Cap
1.41B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 163 | 70 | 75.27% |
Dec 31, 2023 | 93 | 25 | 36.76% |
Dec 31, 2022 | 68 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
GPCR News
- 4 weeks ago - What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? - Benzinga
- 6 weeks ago - Biotech stocks have been hit hard. Why they're a great value now. - Market Watch
- 7 weeks ago - Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate - Seeking Alpha
- 3 months ago - Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 4 months ago - Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst - Benzinga
- 5 months ago - Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity - GlobeNewsWire
- 6 months ago - Structure Therapeutics to Participate in the Jefferies London Healthcare Conference - GlobeNewsWire
- 6 months ago - Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity - GlobeNewsWire